A fake news has been doing rounds on different social mediums saying that Bharat Biotech Vice President Dr V.K. Srinivas has taken Covid-19 vaccine as part of the vaccine's clinical trial.
"Zydus has already manufactured clinical good manufacturing practice (GMP) batches of the vaccine candidate and plans to initiate the clinical trials in July 2020 across multiple sites in India in over 1,000 subjects", the company said.
Bhargava further added that this is "one of the top priority projects which is being monitored that the topmost level of the government" and any kind of non-compliance from the chosen institutes "will be viewed very seriously".
Basically, human clinical trials are conducted to understand the efficacy of the vaccine developed and check on the possible adverse effects, he said.
No coronavirus vaccine has been approved yet for commercial use anywhere in the world.
India's first indigenous Covid-19 antibody (BBV152 COVID immunization) might be launched by August 15.
The ICMR official said the aim was to complete all trials on the vaccine candidate by August 15.
ICMR DG Balram Bhargava, in a letter to heads of hospitals where the vaccine-being developed jointly by Bharat Biotech and ICMR-is to be tested, said the first COVID-19 vaccine is envisaged to be launched by August 15 for which all approvals need to be fast-tracked.
Mukti cited the limited production capabilities and capacities of biotech companies worldwide, and "challenges" to the global supply chain as reasons for the necessity of Indonesia developing its own vaccine. While many expect science to find a quick-fix, experts envisage 12-18 months to get a vaccine commercialised, if at all. Some media reports this week said the United States government is pressurising the regulatory agencies to give faster approvals so that the vaccine reaches the market before the U.S. elections. While this is not the first time that countries have made vaccines under development available to the military even before the completion of the trial, there is growing concern that speeding up vaccine development by bypassing certain crucial stages of the trial process may prove counterproductive. The first and second phase of its clinical human trials are scheduled to begin from July. In the case of COVID-19, regulatory agencies are fast-tracking approvals, but still the vaccines under trials are not expected to reach the market before next year.